A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Immodulon Therapeutics Ltd
ClinicalTrials.gov Identifier:
NCT01539824
First received: February 22, 2012
Last updated: January 28, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to investigate the safety and effects of IMM 101 in combination with a single targeted dose of radiation in patients with metastatic colorectal cancer in whom chemotherapy or other treatment has not been effective. Administration of radiation (using the CyberKnife) to the target tumour growth in the liver results in the release of tumour material. IMM-101 may help the immune system to react to the tumour material released from the damaged tumour, and so have a beneficial effect in slowing down the rate of growth of other tumour growths in the liver and other organs.


Condition Intervention Phase
Metastatic Colorectal Cancer
Biological: Mycobacterium obuense
Radiation: SBRT
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Single Arm, Investigative Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Patients With Previously Treated Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Immodulon Therapeutics Ltd:

Primary Outcome Measures:
  • Disease stabilisation rate [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    The disease stabilisation rate at 24 weeks defined as the proportion of patients with a complete response, partial response or stable disease in accordance with immune-related response criteria.


Secondary Outcome Measures:
  • safety and tolerability profiles [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]

    No clinically relevant deleterious effect of IMM-101 on safety and tolerability profiles as judged by:

    • Local and systemic toxicities.
    • Number, type and degree of toxicities as measured by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v4.0.

    Safety and tolerability will be monitored through the study by a Data Monitoring Committee (DMC)


  • Objective response rate [ Time Frame: 12, 24, 36 and 48 weeks ] [ Designated as safety issue: No ]
  • Disease stabilisation rate [ Time Frame: 12, 36 and 48 weeks ] [ Designated as safety issue: No ]
  • Overall disease stabilisation rate [ Time Frame: End of study ] [ Designated as safety issue: No ]
  • Overall response rate [ Time Frame: End of study ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: 12, 24, 36 and 48 weeks ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: 12, 24, 36 and 48 weeks ] [ Designated as safety issue: No ]
  • Tumour Markers [ Time Frame: 12, 24, 36 and 48 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 29
Study Start Date: February 2012
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMM-101 plus SBRT Biological: Mycobacterium obuense
IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
Other Name: IMM-101
Radiation: SBRT
The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
Other Names:
  • stereotactic body radiation
  • CyberKnife

Detailed Description:

Radiotherapy given in standard fractionation regimes leads to cell death by causing double stranded DNA breaks via production of oxygen free radicals. At the very high doses of stereotactic body radiotherapy (SBRT) administered with extreme accuracy in a single fraction by the CyberKnife system, there is induction of tumour necrosis due to endothelial cell damage and vascular collapse, cell membrane breakdown, and the release of cellular material and tumour antigens into the circulation, in addition to DNA strand breaks. It is hypothesised that the combination of modulation of the body's immune responses in the presence of an increased exposure to tumour antigen will provide sufficient induction of the immune system to suppress tumour growth.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Patients are eligible to be included in the study if they:

  1. Are male or female; aged ≥ 18 years.
  2. Have a histologically confirmed colorectal adenocarcinoma.
  3. Have documented evidence of disease progression following at least one line of chemotherapy.
  4. Have no further standard chemotherapy options available have refused further chemotherapy.
  5. Have metastatic lesions in at least two sites in the liver (+/- other sites) suitable for bidimensional and volumetric evaluation by CT scan.
  6. Have WHO performance status of 0-2.
  7. Have a Cockcroft calculated Glomerular Filtration Rate of > 40mL/min at screening.
  8. Have a life expectancy, in the opinion of the Investigator, of > 3 months from screening.

Patients are not eligible if one or more of the following statements are applicable:

  1. Patient has evidence of central nervous system metastasis.
  2. Patient has severe, active uncontrolled infection requiring systemic antibiotics, antiviral or antifungal treatments.
  3. Patient has any previous or concurrent malignancy, except adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin and/or non-melanoma skin cancer, or if previous malignancy was more than 5 years earlier and there are no signs of recurrence.
  4. Patient has serum albumin < 30 g/L at screening.
  5. Patient has a C-reactive protein (CRP) > 70 mg/L at screening.
  6. Patient has transaminases (ALT or AST) > 5 X Upper Limit of Normal at screening.
  7. Patient has a bilirubin level > 2 X Upper Limit of Normal at screening.
  8. Patient has had radiotherapy in the 12 weeks before screening.
  9. Patient has used depot corticosteroids in the 6 weeks before screening.
  10. Patient has had chronic use of any systemic corticosteroids (> 10 mg per day of prednisolone or equivalent for a period of 2 weeks or more) and/or immunosuppressant drugs (such as azathioprine, tacrolimus, cyclosporin) within the 2-week period before the first administration of study drug.
  11. Patient of child-bearing potential who is not using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]). Those patients that utilise hormonal contraceptives must have used the same method for at least three months before study dosing. Patients of non-child-bearing potential are defined as having 12 month amenorrhoea or are surgically sterile.
  12. Patient who is pregnant, breast feeding or planning a pregnancy during the course of the study. Where appropriate, a pre-treatment serum pregnancy test measuring human chorionic gonadotrophin (hCG) must be negative.
  13. Patient has been administered any investigational product in the 3 months before screening.
  14. Contraindication to CT scan, e.g., allergy to iodine based contrast medium.
  15. Patient has a surgical or medical condition which, in the judgement of the Investigator, might interfere with the activity of IMM-101, or with the performance of this study.
  16. Patient has presence of any uncontrolled concomitant disease (e.g., unstable angina pectoris, congestive heart failure, myocardial infarction, cardiac arrhythmias, uncontrolled severe hypertension) which, in the judgement of the Investigator, might interfere with the activity of IMM-101, or with the performance of this study.
  17. Patient has a history of serious adverse reaction or serious hypersensitivity to any drug that in the opinion of the Investigator may raise a safety concern.
  18. Patient has had any previous treatment with IMM-101 or related mycobacterial immunotherapy (prior BCG vaccination against TB is allowed).
  19. Patient is known to have a history of human immunodeficiency virus (HIV) or syphilis, current symptomatic Hepatitis B or C.
  20. Patient is unable or unwilling to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01539824

Locations
United Kingdom
The London Clinic
London, United Kingdom
HCA International, The Sarah Cannon Research Institute
London, United Kingdom, W1G 6AD
Sponsors and Collaborators
Immodulon Therapeutics Ltd
Investigators
Principal Investigator: Andrew Gaya Leaders In Oncology Care, Harley St, London
  More Information

No publications provided

Responsible Party: Immodulon Therapeutics Ltd
ClinicalTrials.gov Identifier: NCT01539824     History of Changes
Other Study ID Numbers: IMM-101-007, 2011-003958-85
Study First Received: February 22, 2012
Last Updated: January 28, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on September 18, 2014